Gülcan GÜNTAŞ, Ayşegül KAYMAK ÖZTÜRK, Büşranur ÇAVDARLI, Senem ÖZTOMURCUK, Nurefsan TALAYHAN, Çiğdem SÖNMEZ

The importance of test variability in acute myeloblastic leukemia: A case report

Akut myeloid lösemi (AML), fenotipik ve genotipik olarak oldukça heterojen olan bir hastalıktır. Bu hastalığa özgü 100den fazla sitogenetik aberasyon ve gen mutasyonu tanımlanmıştır (1). Hastanemiz hematoloji polikliniğine çeşitli şikayetlerle başvuran hastaya AML tanısı konulmuştur. Bunu takiben yapılan genetik analizlerde t(8;21) ve FLT3-ITD pozitif bulunmuştur. Ayrıca kromozom analizinde trizomi 8 gözlenmiştir. Hastada remisyon sağlandıktan sonra allojenik kök hücre transplantasyonu yapılmıştır. Düzenli aralıklarla hastanın kimerizm, t(8;21), FLT3 mutasyon ve trizomi 8 analizleri yapılarak relaps ve minimal rezidüel hastalık hakkında önceden bilgi sağlamak amaçlanmıştır

Akut miyeloblastik lösemi tanısında test çeşitliğinin önemi: Bir olgu sunumu

Acute myeloid leukemia (AML), phenotypically and genotypically is a quite heterogeneous disease. More than 100 cytogenetic aberrations and gene mutations that are specific to this disease are defined (1). A patient who applied to hematology polyclinic of our hospital with various complaints was diagnosed with AML. In genetic analyses, t(8;21) and FLT3-ITD were found to be positive. Additionally, in chromosome analysis trisomy 8 was observed. After remission was ensured in the patient, allogenic stem cell transplantation was carried out. By conducting t(8;21), FLT3 mutation and trisomy 8 analyses on the patient at regular intervals, prior information was gathered about the relapse and minimal residual disease.

PDF

___

1. Buccisano F, Maurillo L, Del Principe MI, Del Poeta G, Sconocchia G, Lo- Coco F, Arcese W, Amadori S, Venditti A. Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. Blood. 2012; 119:332-41.
2. NCCN Clinical Practice Guidelines in Oncology: Acute Myeloid Leukemia Version 2.2013.
3. Perea G, Lasa A, Aventín A, Domingo A, Villamor N, Queipo de Llano MP, Llorente A, Juncà J, Palacios C, Fernández C, Gallart M, Font L, Tormo M, Florensa L, Bargay J, Martí JM, Vivancos P, Torres P, Berlanga JJ, Badell I, Brunet S, Sierra J, Nomdedéu JF; Grupo Cooperativo para el Estudio y Tratamiento de las Leucemias Agudas y Miel. Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21) and inv(16)]. Leukemia. 2006; 20:87-94.
4. Schnittger S, Schoch C, Dugas M, Kern W, Staib P, Wuchter C, Löffler H, Sauerland CM, Serve H, Büchner T, Haferlach T, Hiddemann W. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood. 2002; 100:59-66.
5. Schnittger S, Kern W, Tschulik C, Weiss T, Dicker F, Falini B, Haferlach C, Haferlach T. Minimal residual disease levels assessed by NPM1 mutation specific real-time quantitative PCR provide important prognostic information in AML. Blood. 2009; 114:2220-31.
6. Campana D, Pui CH. Detection of minimal residual disease in acute leukemia: methodological advances and clinical significance. Blood. 1995; 85:1416-34.
7. Campana D. Determination of minimal residual disease in leukemia patients. Br J Haematol. 2003; 121:823-8.
8. Al-Mawali A, Gillis D, Lewis I. The use of receiver operating characteristic analysis for detection of minimal residual disease using five-color multiparameter flow cytometry in acute myeloid leukemia identifies patients with high risk of relapse. Cytometry B ClinCytom. 2009; 76:91-101.
9. Cheson BD, Bennett JM, Kopecky KJ, Büchner T, Willman CL, Estey EH, Schiffer CA, Doehner H, Tallman MS, Lister TA, Lo-Coco F, Willemze R, Biondi A, Hiddemann W, Larson RA, Löwenberg B, Sanz MA, Head DR, Ohno R, Bloomfield CD. International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia: revised recommendations of the International Working Group for diagnosis, standardizations of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J ClinOncol. 2003; 21:4642-9.